 |
| Pituitary Cancer Market |
The pituitary cancer market is estimated to be valued at US$ 380.7 Mn in 2023 and is expected to exhibit a CAGR of 9.6% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Pituitary cancer is a rare form of cancer that develops in the pituitary gland,
located at the base of the brain. The pituitary gland produces hormones that
regulate important bodily functions such as growth, blood pressure, temperature
regulation and production of other hormones. Pituitary cancer treatment
involves surgery, radiation therapy and medication depending on the type and
stage of cancer. Surgery to remove the tumor is the most common treatment
option. Medications help control hormone levels and radiation therapy is used
to destroy any remaining cancer cells.
Market Dynamics:
Increasing incidence rates of pituitary cancer globally is expected to drive
the market growth over the forecast period. According to statistics, the
incidence of pituitary adenoma ranges from 57.6 to 94.5 cases per million
population per year. Early diagnosis is crucial for effective treatment of
pituitary cancer. However, symptoms of pituitary cancer are not always evident
in early stages which makes early diagnosis challenging. Development of
advanced diagnostic techniques with high sensitivity and specificity can help
detect pituitary cancer at an early stage and enable timely treatment
initiation. Additionally, ongoing research for development of novel targeted
therapies with improved safety profiles is also expected to boost the market
growth during the forecast period.
SWOT Analysis
Strength: Pituitary cancer is a rare type of cancer with few treatment options
available. The low prevalence of the disease and focused research efforts
represent strengths for drug developers. Existing drugs for other cancers and
hormonal disorders are being repurposed for pituitary cancer, reducing
development costs and timelines.
Weakness: Due to the low prevalence of pituitary cancer, patient populations
for clinical trials are small, making trial design and drug approval
challenging. Existing treatment options have limited efficacy and mostly aim to
control tumor growth rather than offer a cure.
Opportunity: An increased understanding of pituitary cancer biology and
identification of molecular targets open potential opportunities for targeted
therapies and personalized treatment approaches. Developing drugs with new
mechanisms of action can address unmet needs and expand treatment options for
patients.
Threats: Competition from other areas of oncology research for funding
represents a threat. Generic versions of repurposed drugs once approved also
pose pricing and market share challenges. Stringent regulatory requirements for
rare cancer approvals also threaten development programs.
Key Takeaways
The global Pituitary
Cancer Market Growth is expected to witness high growth, exhibiting CAGR of 9.6% over the forecast period,
due to increasing research investments for improving treatment outcomes.
Regional analysis
North America currently dominates the pituitary cancer market due to growing
clinical trial activities for novel therapies and availability of advanced
healthcare facilities in the region. Europe is the second largest market owing
to rising prevalence of pituitary disorders and cancer. Asia Pacific is
emerging as the fastest growing market for pituitary cancer treatment
attributed to improving healthcare infrastructure and increasing expenditure on
cancer care.
Key players
Key players operating in the pituitary cancer market are Novartis International
AG, Pfizer Inc., Merck & Co., Inc., Ipsen Biopharmaceuticals, Inc., Bayer
AG, Novo Nordisk A/S, Eli Lilly and Company, Bristol Myers Squibb Company, F.
Hoffmann-La Roche Ltd, Takeda Pharmaceutical Company Limited, Teva
Pharmaceutical Industries Ltd., Sanofi SA, AstraZeneca PLC, Eisai Co., Ltd.,
Janssen Pharmaceuticals, Inc. (Johnson & Johnson). These players are
focusing on new product launches and acquisitions to strengthen their portfolio
of pituitary cancer drugs.
Read More,
https://www.trendingwebwire.com/pituitary-cancer-market-trends-size-and-share-analysis/
0 Comments